Oman Journal of Ophthalmology

CLINICAL IMAGE
Year
: 2012  |  Volume : 5  |  Issue : 1  |  Page : 53--54

Retinal vasoproliferative tumor with total retinal detachment managed with plaque radiotherapy


Stephanie J Nickerson1, Saad A Al-Dahmash2, Carol L Shields1, Jerry A Shields1,  
1 Department of Ocular Oncology Service, Wills Eye Institute, Thomas Jefferson University Philadelphia, PA, USA
2 Department of Ocular Oncology Service, Wills Eye Institute, Thomas Jefferson University Philadelphia, PA, USA; Department of Ophthalmology, College of Medicine, King Saud University, Saudi Arabia

Correspondence Address:
Carol L Shields
Department of Ocular Oncology Service, Suite 1440, Wills Eye Institute, 840 Walnut Street, Philadelphia, PA 19107, USA




How to cite this article:
Nickerson SJ, Al-Dahmash SA, Shields CL, Shields JA. Retinal vasoproliferative tumor with total retinal detachment managed with plaque radiotherapy.Oman J Ophthalmol 2012;5:53-54


How to cite this URL:
Nickerson SJ, Al-Dahmash SA, Shields CL, Shields JA. Retinal vasoproliferative tumor with total retinal detachment managed with plaque radiotherapy. Oman J Ophthalmol [serial online] 2012 [cited 2019 Sep 17 ];5:53-54
Available from: http://www.ojoonline.org/text.asp?2012/5/1/53/94773


Full Text

 Introduction



A 22-year-old female developed painless vision loss right eye (OD). Visual acuity was counting fingers OD, 20/20 OS. The OS was entirely normal. Examination of OD disclosed an orange-colored retinal mass located inferotemporally, measuring 7 mm in basal diameter and 4 mm in thickness [Figure 1]. There was a shallow nonrhegmatogenous total retinal detachment, intraretinal/subretinal exudation, preretinal hemorrhage and macular edema. The features were consistent with a retinal vasoproliferative tumor (VPT) and treatment with Iodine I-125 plaque radiotherapy with a dose of 4000 cGy was provided. Eleven months later, visual acuity had improved to 20/30 OD with tumor involution and resolution of subretinal fluid and macular edema. Four years later, visual acuity was 20/20 with stable findings and complete regression of the VPT to a 2.0-mm thick fibrous nonvascular mass [Figure 2]. There was no evidence of radiation maculopathy or papillopathy.{Figure 1}{Figure 2}

 Comment



Retinal VPT has become a widely recognized entity in recent years. [1],[2],[3],[4],[5] In 1983, 12 cases were reported under the name presumed acquired retinal hemangioma, and the clinical features were thoroughly described. [1] In 1995, the same group reported 129 VPTs in 103 patients and classified this lesion into primary and secondary types. [2] This benign vascular mass has no predilection for gender, generally found in the inferotemporal periphery, and it can lead to serious complications including vision loss from subretinal fluid, exudation and retinal edema. [1],[2],[3] Management includes observation for asymptomatic lesions or laser photocoagulation, cryotherapy, photodynamic therapy or plaque radiotherapy for symptomatic tumors. [1],[2],[3],[4],[5]

Cohen and associates reviewed 30 eyes with a VPT treated with Iodine I-125 plaque radiotherapy and found tumor regression in 97% of cases, resolution of retinal detachment in 65% and improvement of visual acuity to 20/40 or better in 37%. [4] In the case reported here, plaque radiotherapy was successful in tumor control and vision return.

References

1Shields JA, Decker WL, Sanborn GE, Augsburger JJ, Goldberg RE. Presumed acquired retinal hemangiomas. Ophthalmology 1983; 90:1292-300.
2Shields CL, Shields JA, Barrett J, De Potter P. Vasoproliferative tumors of the ocular fundus: Classification and clinical manifestations in 103 patients. Arch Ophthalmol 1995;113:615-23.
3Damato B. Vasoproliferative retinal tumour: Brachytherapy requires further evaluation. Br J Ophthalmol 2006;90:399-400
4Cohen VM, Shields CL, Demirci H, Shields JA. Iodine I 125 plaque radiotherapy for vasoproliferative tumors of the retina in 30 eyes. Arch Ophthalmol 2008;126:1245-51.
5Anastassiuo G, Bornfeld N, Schueler AO, Schilling H, Weber S, Fluehs D, et al. Ruthenium-106 plaque brachytherapy for symptomatic vasoproliferative tumours of the retina. Br J Ophthalmol 2006;90:447-50.